I can help you assess this analytical-method change end to end. Tell me what's changing and I'll trace the impact across the Brain, flag the risks, and build the change task list with you.

What's the change you're proposing for Aspirin?

Got it — a method change plus a spec tightening. Let me look across what the Brain holds for Aspirin and trace where this lands.

Here's the impact I can see so far:

The first two are grounded in Aspirin's own records. The stability point is an assumption I've drawn from public sources — worth confirming before it goes in the task list. Want me to draft the task list now?

Here's a first draft. Each task carries where it came from, so a reviewer can see the basis.

Task 4 is flagged provisional — it exists because of the assumption, not a verified finding. When you're happy, use Write back → to propose this to the Brain.

This is the open way in — an ordinary conversation with the Aspirin Brain, for anything a purpose-built agent doesn't cover. I draw on the same knowledge and flag verified versus provisional the same way.

Ask me anything about this product.

Across the last 24 release batches it runs 0.04–0.08%, comfortably under the current 0.15% limit. Verified

Probably not at release, but I can't answer the shelf-life half from your own records. Aspirin hydrolyses to salicylic acid over time, and published stability work suggests end-of-life values typically sit 0.03–0.05% above release. Provisional